Deudextromethorphan - Avanir Pharmaceuticals

Drug Profile

Deudextromethorphan - Avanir Pharmaceuticals

Alternative Names: AVP-786; CTP-786; d-DM; Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]; Deuterated dextromethorphan plus ultra low dose quinidine; Deuterated DM plus ultra low dose quinidine; Deuterated-dextromethorphan; Deuterated-DM

Latest Information Update: 11 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Concert Pharmaceuticals
  • Developer Avanir Pharmaceuticals
  • Class Antidepressants; Antipsychotics; Antitussives; Morphinans; Neuroprotectants; Opioid analgesics; Organic deuterium compounds; Small molecules
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; KATP channel inhibitors; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists; Sigma-1 receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Agitation
  • Phase II Brain injuries; Major depressive disorder; Neurodegenerative disorders; Schizophrenia
  • Phase I Neuropathic pain
  • Preclinical Psychiatric disorders

Most Recent Events

  • 13 Oct 2017 Phase-III clinical trials in Agitation in Australia (PO) (NCT03393520)
  • 30 Sep 2017 Phase-III clinical trials in Agitation in European Union (PO) before September 2017 (Otsuka Pharmaceutical pipeline, November 2017)
  • 01 Aug 2017 Avanir Pharmaceuticals completes a phase II trial in Schizophrenia (Adjunctive treatment) in USA (PO) (NCT02477670)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top